Plain-English translation of NCT07422779 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether , , or a combination of plus can effectively treat melanoma that has spread to other parts of the body. Researchers also want to understand whether certain markers in your blood and tumor tissue can predict which patients will respond best to the medication, and how side effects relate to survival outcomes.
While these immune-boosting medications have shown promise for advanced melanoma, doctors need better ways to predict which patients will benefit most and to understand the relationship between side effects and treatment success. This study aims to fill that gap and improve how these drugs are used in clinical practice.
You likely qualify if…
You likely don't qualify if…
You will receive one of the immune-boosting medications as your standard cancer treatment, either as a single drug or a combination of two drugs, depending on what your doctor recommends. The study will track how well the treatment works by monitoring your scans and blood tests, and researchers will collect blood and tumor samples to analyze the markers they're studying. You'll be followed as part of your regular cancer care, with visits and tests scheduled according to standard treatment protocols.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Slovenia
Sponsor
Institute of Oncology Ljubljana
Enrollment target
~100 participants
Started
March 2022
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tanja Mesti, MD
Institute of Oncology Ljubljana
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.